Please login to the form below
Alcon
This page shows the latest Alcon news and features for those working in and with pharma, biotech and healthcare.
Novartis aims for 10 blockbuster launches by 2020
The company also announced cuts to its manufacturing operations, and confirmed the spin off of eyecare division Alcon, which could raise as much as $35bn this year.
Latest news
-
Novartis sells off part of Sandoz portfolio
from its eye-division Alcon, which it acquired back in 2010.
-
GSK: we won’t be splitting up any time soon
The decision is in contrast to firms such as Novartis (selling its eyecare divison Alcon) and Lilly, which just announced the spin-off its animal health division Elanco.
-
Novartis follows Pfizer and freezes US prices this year
ploughing the cash back into the pipeline-enriching acquisitions of gene therapy company AveXis and radiopharma specialist Advanced Accelerator Applications – and going ahead with the spin-off its Alcon eyecare unit.
-
Alcon spin-off prompts Novartis downgrade by Moody’s
Selling off Alcon concentrates business in riskier areas. Not everyone thinks Novartis spinning off its Alcon eyecare unit is a good idea.In fact, Moody’s has just downgraded the ... To that end Novartis is hanging onto Alcon’s prescription drug
-
GSK buys Novartis out of consumer health JV after ditching Pfizer bid
Novartis has also said it intends to spin off its Alcon eyecare unit and the latest deal has added to speculation it may now consider parting with its 6% stake in
More from news
Approximately 17 fully matching, plus 49 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
To date it seems Sanofi is also considering a move. Meanwhile Novartis is reportedly considering a sale of its contact lens business which is part of the Alcon eye care division.
-
Pharma deals during April 2014
Remaining revenues will come from pharmaceuticals, eye care (Alcon) and generics (Sandoz) and of course its stake in GSK Consumer Health.
-
Healthcare industry apps
Developed by Alcon (a Novartis company) this comprehensive tool is designed to teach doctors how to make diagnoses using an ophthalmoscope.
-
Interview: Joseph Jimenez, Novartis
Our new eye-care business Alcon is also driving our growth, with net sales increasing six per cent in Q2.". ... Alcon is already delivering solid sales growth, with sales up six per cent on a proforma basis in the second quarter.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Agios appoints Celgene’s Jackie Fouse
Prior to her tenure at Celgene, Fouse worked for Alcon Laboratories, an ophthalmic pharmaceutical and medical device company.
-
Celgene’s president and COO to retire
Previously, Dr Fouse was chief financial officer of agribusiness and food company Bunge, and also brought executive leadership expertise from Alcon Laboratories and Nestlé.
-
Dr Robert Kim joins Apellis as chief medical officer
Meanwhile, at he served at GSK as VP of clinical ophthalmology, helping build its early stage clinical pipeline, and was VP and head of pharmaceutical product development at Novartis/Alcon.
-
Novartis makes trio of appointments to senior leadership team
Ball has been appointed as the new division head and chief executive officer of Alcon, replacing Jeff George, and is set to focus on its surgical and vision care division. ... Joseph Jimenez, chief executive officer of Novartis, said: “His expertise in
-
Novaliq GmbH appoints Friedrich von Bolen as chairman
Prior to his appointment as a board member of Novaliq, Dr Cagle was senior vice president of Alcon R&D and chief scientific officer from 1996 to mid-2008 having worked ... as a member of Alcon's research and development team for over thirty years.
More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest from PMHub
-
Random42 Scientific Communication
Abbott. Abbvie. Advanced Bionics. Abivax. Alcon. Alkermes. Alnylam. Allergan. Amgen. Anika Therapeutics. ... Everyone is very impressed!". - Global Product Manager, Alcon. "This MOA sets a new bar for such work.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
-
Digital Account Director
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Project Manager/ Account Manager
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
- Drug launches to watch in 2019
- Welcome to the Communique Awards - Communiqué Awards 2018
- ‘Inflexible’ NICE blocking access to rare disease drugs
- 2019: CRISPR and therapeutic gene editing comes of age
- GW Pharma's cannabis-based medicine to be tested in dementia
- More good news, and some bad, for Merck’s Keytruda
- BioMarin prepares for haemophilia A gene therapy data readout, filing
- Innovent gears up for PD-1 inhibitor launch in China
- NICE knocks back BioMarin’s Batten disease drug
- Amgen, Servier start second phase 3 trial of heart failure hope
- The importance of co-creation with patients
- McCann Health's next challenge: creative differentiation
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- The importance of co-creation with patients
- Overcoming the barriers...
- Three billboards on the road to multichannel
- Chris Ross examines the trends driving multichannel communication in 2019...
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
